Navigation Links
AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
Date:10/29/2010

lan," "goal," "expect," "project," or similar statements, may be forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results expressed or implied by such statements. These statements include, but are not limited to, AVANIR's ability to successfully market and sell NUEDEXTA in the United States, the safety and efficacy of NUEDEXTA, and the anticipated timing and success of the commercial launch of NUEDEXTA. Risks that could cause actual results to differ include the occurrence of adverse safety events with NUEDEXTA, our limited capital resources, our dependence on third parties for manufacturing and distribution of NUEDEXTA, that we may not adequately build or maintain the necessary sales, marketing, supply chain management and reimbursement capabilities on our own or enter into arrangements with third parties to perform these functions in a timely manner or on acceptable terms, and other risks that are described in further detail in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and from time-to time in other publicly available information regarding the Company. Copies of this information are available from us upon request. We disclaim any intent to update these forward-looking statements.


'/>"/>
SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) ... November 30, 2013, compared to sales of $2,202,000 for the ... again, this quarter has also shown growth over the preceding ... quarter of this fiscal year. Markets that experienced sales increases ...
(Date:1/15/2014)... 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... support, China,s orthopedic instrument industry ... market size rising from 3.28 billion yuan in 2006 ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
Breaking Medicine Technology:Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
(Date:7/10/2014)... For decades, health-conscious people around the globe have taken ... this was one of the paths to good health ... trials of antioxidant supplements have repeatedly dashed the hopes ... cancer risk. Virtually all such trials have failed ... fact, in several trials antioxidant supplementation has been linked ...
(Date:7/10/2014)... Depressed men with localized prostate cancer were more ... cancer, received less effective treatments and survived for ... not depressed, a UCLA study has found. , ... several factors such as bias against the mentally ... depressed man,s lack of investment in his general ...
(Date:7/10/2014)... Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute ... a new therapeutic combination to combat resistant sarcomas. The ... could stabilize the growth of these tumors have been ... Cancer ., Sarcomas , Sarcomas are a rare ... subtypes. It can affect from children to older ages. ...
(Date:7/10/2014)... and cakes that are just as tempting as ... thanks to fresh insights into how proteins can ... , Funded by the Engineering and Physical ... University and the University of Edinburgh has produced ... and therefore closely mimic the behaviour of fats ...
(Date:7/10/2014)... new drug could prove useful in treating small cell lung ... Scientists from the Cancer Research UK Manchester Institute, based at ... Research Centre, teamed up with experts at AstraZeneca, as part ... known as AZD3965 - on small cell lung cancer ... Cancer Research , also helps identify which patients are most ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:New drug active against most aggressive type of lung cancer cells 2
... National Council on,Disability (NCD) today invited the Boston disability ... will take place at,the Hyatt Regency Boston, One Avenue ... 8:30 a.m. until 5:00 p.m.; Friday,November 30 from 8:30 ... a.m. until 11:15 a.m., Public comment sessions will ...
... IRVINE, Calif., Nov. 9 Masimo (Nasdaq: MASI ... Low Perfusion,pulse oximetry, announced today that the Pricing Committee ... rights plan. "This plan is designed to enhance ... acquire control of the company,that do not offer an ...
... N.C. and ALPHARETTA, Ga., Nov. 9 ... diagnostic imaging,services, officially joined Novant Health today ... acquisition. MedQuest will operate as a,wholly-owned subsidiary ... not-for-profit integrated healthcare system serving,North and South ...
... 9, 2007) A gender difference exists among surgeons ... the factors that may influence their career choice, according ... November issue of the Journal of the American College ... higher percentage of women than men were influenced by ...
... effective in easing pain, study finds , FRIDAY, Nov. 9 ... reduce disease activity and pain in patients with chronic active ... of 10 patients, average age 62, who had gout for ... by Dr. Robert Terkeltaub of the VA Medical Center and ...
... 8th annual gala and auction November 16 to benefit Girls ... to kayak, golf, run, bike,dine, relax, shop, travel and more ... Go Girl Gala, taking place Friday November 16 at the,Chicago ... and fitness enthusiasts, features live music from the Underwater,People, cocktails, ...
Cached Medicine News:Health News:Masimo Corporation Adopts Stockholder Rights Plan 2Health News:Masimo Corporation Adopts Stockholder Rights Plan 3Health News:Novant Health Completes Purchase of MedQuest 2Health News:Novant Health Completes Purchase of MedQuest 3Health News:Survey shows gender differences are factor when surgeons in training choose a subspecialty 2Health News:Chicago's Premier Sports and Fitness Auction is Back! 2
... System Produces Type I Water Directly from Tap, ... for scientists who need 5 to 15 L ... have easy access to acceptable quality pretreated water. ... L/min of ultrapure (Type I) water on demand, ...
... speed, stability and durability. Back-lighted Display. ... multiple units of measure, piece counting ... and GLP/GMP/ISO output including date and ... calibration with external weights only (selectable ...
... weighing mechanism for speed, stability and ... analog display modes, multiple units of ... functions, auto print, and GLP/GMP/ISO output ... built-in clock. Built-in, motor-driven internal ...
... - Battery Powered (6 size AA required). ... (g, ct, oz, ozt, GN, dwt, mom, ... and Percent Measure functions, Auto Print. Optional ... AC adapter may be ordered for AC ...
Medicine Products: